Biofrontera Inc. re-affirmed earnings guidance for 2022. The company maintains its previously announced financial guidance for 2022, as total revenues are expected to increase by at least 30% compared with 2021, including typical seasonal strength in the first and fourth quarters. The commercial focus throughout 2022 will be on achieving deeper sales penetration among current customer accounts, with additions to the Biofrontera sales force expected to begin in 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 USD | -6.98% | -13.04% | -42.24% |
03-18 | Transcript : Biofrontera Inc., Q4 2023 Earnings Call, Mar 18, 2024 | |
03-15 | Biofrontera Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.24% | 8.75M | |
+33.43% | 690B | |
+26.43% | 546B | |
-5.12% | 358B | |
+19.59% | 323B | |
+4.89% | 287B | |
+14.32% | 235B | |
+5.79% | 199B | |
-9.49% | 195B | |
+4.26% | 161B |
- Stock Market
- Equities
- BFRI Stock
- News Biofrontera Inc.
- Biofrontera Inc. Re-Affirms Earnings Guidance for 2022